Updated Results of TCAR Surveillance Project Presented at 2019 VEITHsymposium
NEW YORK, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at the VEITHsymposium. In a headline presentation, Dr. Mahmoud Malas of the University of California, San Diego School of Medicine shared updated results for the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project contemporaneously comparing TCAR to the surgical standard of care, carotid endarterectomy (CEA).
Read More: https://www.globenewswire.com/news-release/2019/11/22/1951528/0/en/Favorable-Outcomes-with-TCAR-vs-Carotid-Endarterectomy-in-Patients-with-Carotid-Artery-Disease.html
BCBS of Minnesota inks deal with Omada to provide Type 2 diabetes tool to members
Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference
Results from Prospective, Multicenter Trial Evaluating the Use of the Tablo® Hemodialysis System for Home Dialysis Released at the American Society of Nephrology Scientific Meeting
Via: PR Newswire
First New Device Trial Completed for Home Hemodialysis In 15 Years